Delivers high-performing AI infrastructure through NVIDIA DGX Cloud Lepton to portfolio companies, creating a powerful competitive advantage in $100B+ life sciences market BioCorteX, Bioptimus, Cure51, and Latent Labs among first cohort of startups to gain GPU capacity credits, helping position Europe at forefront of AI-driven drug discovery revolution PARIS, France – June, 11, 2025 – […]
Leading European venture capital firm exceeds €4 billion in assets under management, doubling its AUM in the last five years PARIS, France – March 4, 2025 — Sofinnova Partners (“Sofinnova”), a leading European venture capital firm in life sciences based in Paris, London, and Milan, today announced it had raised €1.2 billion across its platform […]
Financing to advance first platform designed to reprogram cancer cells into immune cells as pan-tumoral cancer treatment Novo Holdings participation follows earlier investment and incubation through seed phase Financing co-led by RV Invest and Johnson & Johnson Innovation, joined by existing investors Boehringer Ingelheim Venture Fund and Industrifonden COPENHAGEN – March 14th, 2024 – Novo Holdings, […]
18 new portfolio investments Five portfolio companies acquired $766 million invested and committed $600 million of cash exit proceeds San Francisco, Boston, London, and Copenhagen, Denmark, 5 March 2024 – The Novo Holdings Venture Investments team today published its review of 2023 – a record year advancing innovative therapies for patients. Read more…
Series A financing led by Pfizer Ventures with new investors Columbus Venture Partners and British Patient Capital which join founding investor Advent Life Sciences and seed investor Epidarex Capital Goal to advance proprietary discovery platform and progress pipeline of assets addressing challenging cancer targets into the clinic Southampton, UK, 27 February 2023 – Curve Therapeutics […]
